March 1998 in “Hair transplant forum international” The document could not be processed or understood.
STS01 1% effectively promotes hair regrowth with minimal side effects.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
2 citations
,
June 2023 in “Journal of cell science” Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Botulinum toxin type A did not help regrow hair in severe alopecia cases.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
16 citations
,
August 2014 in “PubMed” January 2019 in “Florida International University Digital Commons (Florida International University)” TOF-SIMS improved chemical mapping in cells, confirming gunshot residue, tracking anti-tumor drugs, and identifying molecules in mosquitoes and wounds.
September 2023 in “Journal of the American Academy of Dermatology”
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
July 2008 in “Hair transplant forum international”
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
ACA from Alpinia galanga may prevent testosterone-related hair loss.
July 2025 in “InnovAiT Education and inspiration for general practice” 9 citations
,
January 2024 in “International Journal of Dermatology” July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
January 2026 in “Dermatologic Therapy” This study investigated the role of tissue Retinol‐Binding Protein 4 (RBP4) and its genetic variant rs3758539 in patients with severe alopecia areata (AA) and their response to baricitinib treatment. The study included 50 patients with severe AA and 50 healthy controls. Results showed that baseline tissue RBP4 levels were significantly higher in patients compared to controls and decreased significantly after baricitinib treatment, especially in responders. Elevated RBP4 levels were associated with higher disease severity. The TT genotype and T allele of rs3758539 were linked to increased susceptibility to severe AA, but this polymorphism did not affect the response to baricitinib treatment.
1 citations
,
February 2013 in “InTech eBooks” LEKTI is crucial for skin barrier and immune function, affecting conditions like Netherton syndrome and atopic dermatitis.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
July 1998 in “Hair transplant forum international” The document's content could not be processed or understood.
2 citations
,
July 1996 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not accessible or understandable.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.